Quote:

---

Maybe DCVax-L by another biotech startup is more targeted for glioblastoma? I'm wondering how the two compare... or how well they may work together...

---

They make DCVax-L by removing the patients own T-cells and exposing them to the content of the patients own tumor cells. This exposure to tumor antigens primes the T-cells to develop antibodies against the tumor so the T-cells recognize the tumor as foreign. The T-cells are then reintroduced into the body. The problem I can see is that glioblastoma tumor cells develop a highly M2 macrophage environment that protects the tumor (including highly expressed PD-L1) making them cold tumors. If the cold tumors were turned hot and the tumor immunosuppressant factors were reduced than DCVax-L would be unnecessary because there would be a rise in killer T-cells that would recognize the antigens and attack. Give those glioblastoma patients leronlimab and ICIs.

I first looked at Northwest Biotherapeutics and a handful of other biopharmaceuticals around a couple of decades ago.I was thinking about diversifying my trading. I released that I did not have a good understanding of the medical side and that biopharmaceuticals could be a minefield. Northwest was fundamental in my coming to that conclusion. The FDA has never really been happy about how the trials were run and their Phase 3 was bad enough it could have been done by Amarex. There's a very high chance that Northwest will have to run another phase 3 if they want to get FDA approval.